We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Moderna (MRNA) Q4: Wall Street Projections for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Moderna (MRNA - Free Report) will announce quarterly loss of $2.65 per share in its forthcoming report, representing a decline of 581.8% year over year. Revenues are projected to reach $956.11 million, declining 66% from the same quarter last year.
The current level reflects an upward revision of 7.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Moderna metrics that are commonly monitored and projected by Wall Street analysts.
The consensus among analysts is that 'Revenue- Net Product sales' will reach $938.66 million. The estimate points to a change of -66.4% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Other revenue' should arrive at $17.14 million. The estimate indicates a change of -4.8% from the prior-year quarter.
According to the collective judgment of analysts, 'Product sales- Rest of world' should come in at $551.12 million. The estimate points to a change of -59.9% from the year-ago quarter.
The combined assessment of analysts suggests that 'Product sales- United States' will likely reach $247.03 million. The estimate suggests a change of -69.3% year over year.
Over the past month, Moderna shares have recorded returns of -9.3% versus the Zacks S&P 500 composite's +4.2% change. Based on its Zacks Rank #3 (Hold), MRNA will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into Moderna (MRNA) Q4: Wall Street Projections for Key Metrics
Analysts on Wall Street project that Moderna (MRNA - Free Report) will announce quarterly loss of $2.65 per share in its forthcoming report, representing a decline of 581.8% year over year. Revenues are projected to reach $956.11 million, declining 66% from the same quarter last year.
The current level reflects an upward revision of 7.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Moderna metrics that are commonly monitored and projected by Wall Street analysts.
The consensus among analysts is that 'Revenue- Net Product sales' will reach $938.66 million. The estimate points to a change of -66.4% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Other revenue' should arrive at $17.14 million. The estimate indicates a change of -4.8% from the prior-year quarter.
According to the collective judgment of analysts, 'Product sales- Rest of world' should come in at $551.12 million. The estimate points to a change of -59.9% from the year-ago quarter.
The combined assessment of analysts suggests that 'Product sales- United States' will likely reach $247.03 million. The estimate suggests a change of -69.3% year over year.
View all Key Company Metrics for Moderna here>>>
Over the past month, Moderna shares have recorded returns of -9.3% versus the Zacks S&P 500 composite's +4.2% change. Based on its Zacks Rank #3 (Hold), MRNA will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>